About US
Contact us
-
Novartis to lay off another 100-plus employees at US HQ as global restructuring rolls onAfter cutting hundreds of jobs in New Jersey around the start of this year, Novartis is at it again. Novartis plans to lay off 103 employees at its its U.S. headquarters in East Hanover,2023/8/14
-
Spanish drugmaker Serra Pamies suffers manufacturing clampdown by EMAProblems with quality management, data integrity, expired raw materials and more have prompted the European Medicines Agency (EMA) to put the kibosh on manufacturing at Serra Pamies’ Reus, Spain, fac2023/8/14
-
Teva, Glenmark reach $255M price-fixing settlement with DOJ, agree to offload certain medsAfter admitting to running a price-fixing scheme as part of a deal with the Department of Justice, not only will generic makers Teva and Glenmark Pharmaceuticals pay hefty fines, but they'll also be2023/8/11
-
Pfizer's Abrysvo becomes first maternal RSV shot to protect newbornsAlready with an approval in hand for older adults, Pfizer’s Abrysvo has become the first vaccine for pregnant women to protect their newborns against respiratory syncytial virus (RSV). Th2023/8/11
-
What infeasible trial? Lilly shows Roche how it's done with positive Retevmo readout in thyroid cancerIt was only a few weeks ago when Roche said a phase 3 study testing its RET inhibitor Gavreto in a type of thyroid cancer was not doable. Now, Eli Lilly has revealed that a similar trial of its own R2023/8/7
-
Roche, Exelixis' Tecentriq-Cabometyx combo rebounds with partial win in previously treated prostate cancerAfter a losing streak in the clinic, Roche and Exelixis’ combo of Tecentriq and Cabometyx has delivered a trial win in tough-to-treat prostate cancer. Roche’s immuno-oncology star Tecentr2023/8/7
-
Regeneron wins FDA approval for rare immune disease med VeopozAlong with resolving site inspection issues that cost Regenerona high-dose Eylea launch in June, the company has scored an FDA nod forVeopoz as the first treatment for the ultra-rare inherited immune2023/8/4
-
On blockbuster mission, Merck says Welireg hit endpoint in renal cell carcinoma trialTwo years after Welireg's original approval in the rare von Hippel-Lindau (VHL) disease, Merck is looking to expand its drug'sreach and turn it into a blockbuster. The drug, which Merck p2023/8/4
-
Moderna's updated COVID shot stands strong against new variants in first look at trial data, company saysVexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape, which includes a shif2023/8/1
-
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4Novartis’ Sandoz spinoff is right around the corner, and, to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme. Roughly a year after disclosing plan2023/8/1